Thanks of the clarification. I maintain that prescribing Lumigan to a self-pay patient who plans to use it for eyelashes does incur some malpractice risk. It’s a small risk but an unnecessary one; hence, I do not expect off-label use of Lumigan for eyelashes to be common, even for self-pay patients. Certainly, it will not reach anywhere near the penetration of off-label Avastin in AMD.
Market Data 
Markets 
AI
